The efficacy and safety of anlotinib treatment for advanced lung cancer

OBJECTIVE: Anlotinib is an oral novel multi-target tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, and stem cell factor receptor (c-Kit). The aim of this study was to evaluate the efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Lan, Wang, Wenxian, Song, Zhengbo, Zhang, Yiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699585/
https://www.ncbi.nlm.nih.gov/pubmed/31616163
http://dx.doi.org/10.2147/OTT.S205674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699585/
https://www.ncbi.nlm.nih.gov/pubmed/31616163
http://dx.doi.org/10.2147/OTT.S205674

Ejemplares similares